logo
TikTok Banned the "SkinnyTok" Hashtag. It's Only a Matter of Time Until a New Insidious Diet Trend Replaces It

TikTok Banned the "SkinnyTok" Hashtag. It's Only a Matter of Time Until a New Insidious Diet Trend Replaces It

Yahoo2 days ago

iantfoto
In this op-ed, Features Director Brittney McNamara considers TikTok's SkinnyTok hashtag ban and the seemingly unbeatable monster of diet culture.
If you've been on social media lately, you undoubtedly know about #SkinnyTok. Along with the rise in popularity of weight loss drugs like Zepbound and Wegovy over the last few years, thinness as an ideal has also returned to our cultural lexicon, spawning a whole hashtag full of creators discussing how they get and stay thin, swapping diet and workout tips that encourage sometimes extreme measures to be skinny.
But on June 3, TikTok banned #SkinnyTok as a search term after concern from European legislators about how the app can negatively impact young people's body image, according to the New York Times. The hashtag had 'become linked to unhealthy weight loss content,' TikTok said in its reasoning for the ban, something the European Commission was investigating because of the potential 'public health risk' associated with promoting 'extreme thinness' to young people online, Politico reports. Now, when users enter that search term, they'll be directed to resources like the National Alliance for Eating Disorders.
We know that social media can negatively affect our mental health, and can contribute to body image issues like body dysmorphia and even eating disorders, so this move is an all-around win. There is no benefit — even if society would like to tell you there is — to promoting extreme thinness or unhealthy diets, things that #SkinnyTok was often associated with. But even though the ban is a net positive in this sense, it's simply a bandaid on a much larger issue. Until we reckon with our cultural obsession with thinness and our wholesale buy-in to diet culture, #SkinnyTok will simply shift and transform, taking on a new slender shape online.
According to Today, #SkinnyTok began appearing on TikTok around the start of this year, gaining steam in March and April. Videos under the hashtag encouraged viewers to eat less, making hunger seem like a virtue and repackaging harmful diet advice as 'tough love." If you weren't dieting and participating in behaviors to make yourself smaller, many #SkinnyTok posts were there to shame you into submission.
It's not clear exactly who started the hashtag, but it is apparent how it gained popularity. Social media and other online forums have long been hotbeds for extreme diet talk and for promoting unhealthy body ideals. In the heyday of Tumblr, 'pro ana' (pro anorexia) and 'thinspo' content abounded. When those topics were banned, users found ways to evade that, substituting letters or words to signal their content to other users without triggering filters that would censor their posts. Meta whistle-blower Frances Haugen revealed internal research that found that 'when [32% of teen girls] felt bad about their bodies, Instagram made them feel worse.' As a result of that information, social media executives testified before Congress in 2021, in part about the ways their platforms impact young people's body image.
Just before #SkinnyTok officially earned its title, content creator Liv Schmidt was ousted from TikTok in October 2024 because of her posts instructing viewers on how to be skinny. Her posts violated TikTok's Community Guidelines, which prohibit '​​promoting disordered eating and dangerous weight loss behaviors.' But before her ban, Schmidt had more than 670,000 followers on TikTok, according to the New York Times. She claimed her instructions on how to eat less with the explicit goal of being thin were simply the pursuit of a certain aesthetic, not a roadmap to potentially disordered eating. Even more recently, Schmidt's group chat called the Skinni Societe was demonetized by Meta after The Cut published an inside look at Schmidt's advice to followers, including lines like "eat like your next weigh-in is tomorrow.'
The resurgence of explicit diet talk and 'thinspo' on social media is evidence of a trend we've seen growing for a while now. The advent of GLP-1 drugs has made weight loss attainable for many, and has made getting even thinner an option for many already-thin people. And, with another Trump administration in office, a focus on thinness in society is no surprise. Research has shown a link between conservative ideology and anti-fatness, something we've seen mirrored in Trump's own language. So it's not necessarily a shock that people with fatphobic ideas would feel emboldened in this time, especially.
TikTok's #SkinnyTok ban is certainly the right move, and it's encouraging to know that people searching for it on that platform will instead be served resources to cope with disordered eating. But as we can see from the long history of disordered eating and 'skinny' content online, this move is likely to remove one threat, only for another to pop up in its wake.
Diet culture is much like the mythological hydra; when you cut one head off of this beast, two more grow in its place. The threats get more numerous, more insidious, the more we strike at it. To truly beat #SkinnyTok and trends like it, we'd need a cultural reckoning — one where we collectively decide that thinness isn't a value, but simply one of many states of being. We'd need to grapple with the racism and anti-Blackness baked into anti-fatness, and how promoting thinness has ties to white supremacy. We'd need to address anti-fat bias in medicine, and rethink the common tropes about fatness and health. We'd need to radically change our thinking, our social structures, our collective stereotypes. We'd need to then cauterize the wounds diet culture has left, making sure no new ugly heads could rear when we turn our backs.
Judging by the current political and social climate, that seems unlikely. It's certainly possible, and maybe one day we'll get there. In the meantime, #SkinnyTok may be dead, but it's only a matter of time before another hashtag or trend telling young people to aspire to thinness crops up, another head of this seemingly unkillable hydra ready to bite us in our ever-smaller butts.
Originally Appeared on Teen Vogue

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

GLP-1 Drugs Linked to Age-Related Macular Degeneration, Study Finds
GLP-1 Drugs Linked to Age-Related Macular Degeneration, Study Finds

Health Line

time8 hours ago

  • Health Line

GLP-1 Drugs Linked to Age-Related Macular Degeneration, Study Finds

GLP-1 drugs are associated with a higher risk of 'wet' age-related macular degeneration in people with type 2 diabetes, according to a new study. Researchers found that the risk substantially increased the longer people were prescribed a GLP-1 drug, particularly those containing semaglutide. GLP-1 medications like Ozempic and Wegovy have surged in popularity as weight loss treatments, but ophthalmologists say their potential risks to eye health are not well understood. GLP-1 drugs are linked to a significantly higher risk of developing neovascular or 'wet' age-related macular degeneration, according to new research. The study, conducted by researchers at the University of Toronto, found that people with type 2 diabetes who were prescribed GLP-1s were more than twice as likely to develop wet AMD as those who weren't. The study also found that the longer subjects were treated with these medications, the greater their risk of developing wet AMD. Neovascular age-related macular degeneration, commonly known as wet AMD, is the less common but more aggressive form of age-related macular degeneration, and a leading cause of irreversible vision loss among older adults in the United States. The findings, published on June 5 in JAMA Ophthalmology, suggest that doctors and patients should be aware of the potential risks, even though the chance of developing the condition remains relatively low. GLP-1 drugs, a class of blockbuster diabetes and obesity drugs sold under brand names like Ozempic and Wegovy, have surged in popularity in recent years. They offer a range of substantial benefits, including weight loss, improved blood sugar levels, and reduced cardiovascular disease risk. Despite these benefits, ophthalmologists say the impact of GLP-1 drugs on eye health is not well understood. Studies have identified an association between the medications and other eye conditions, including diabetic retinopathy and non-arteritic anterior ischemic optic neuropathy (NAION). While the findings don't establish a clear causal link between GLP-1 drugs and eye disease, experts say there's still reason for caution. 'The dose-response effect we observed — where longer GLP-1 receptor agonist exposure was associated with higher risk — strengthens the argument that this association may reflect a true biological effect rather than being due to confounding factors,' said study co-author Andrew Mihalache, MD(C), of the Temerty Faculty of Medicine at the University of Toronto, Canada. 'Seeing a graded relationship like this suggests that prolonged exposure could play a causal role in increasing risk. However, this needs to be confirmed in future studies,' he told Healthline. Long-term GLP-1 drug use may triple wet AMD risk Drawing on health records from Ontario, Canada, researchers at the University of Toronto analyzed nearly 140,000 adults with type 2 diabetes to investigate a possible link between GLP-1 use and wet AMD. The retrospective study tracked patient outcomes over a three-year period, using data collected between 2020 and 2023. Roughly one-third of participants — about 46,000 people — had been prescribed a GLP-1 drug for at least six months. The rest had not. In the vast majority of cases (97.5%), that drug was semaglutide, the active ingredient in Ozempic and Wegovy. The average participant was 66, and the cohort was almost evenly divided by sex, with females representing 46.6% of the group. On average, those who were prescribed a GLP-1 drug were more than twice as likely to be diagnosed with wet AMD. However, that number doesn't tell the full story. People who took GLP-1 drugs for longer experienced progressively greater risk. Those who had only taken their medication for 6–18 months actually had a slightly lower risk than those who didn't take the medication. However, at the 18–30 month mark, GLP-1 users' risk of developing wet AMD more than doubled compared to non-users. And those taking the drugs for 30 months or longer had more than triple the risk. 'This was definitely surprising, especially given the growing enthusiasm for GLP-1 receptor agonists for their cardiovascular and metabolic benefits. It really highlights the need for further investigation into their ocular safety profile,' first study author Reut Shor, MD, of the Department of Ophthalmology and Vision Sciences at the University of Toronto, Canada, told Healthline. Despite the increase in risk, the absolute risk of developing wet AMD was still low: 0.2% among those taking a GLP-1 and 0.1% among those who didn't. Do GLP-1 drugs harm eye health? While not definitive, the study raises further questions about the potential risks posed by GLP-1 drugs for eye health. Prior studies have also identified links between GLP-1s and other forms of eye disease in people with type 2 diabetes. In a major phase 3 semaglutide trial in 2016, researchers identified that type 2 diabetes patients taking semaglutide had a higher risk of complications of diabetic retinopathy compared to a placebo. Those findings were published in The New England Journal of Medicine. However, other studies have provided conflicting evidence. A retrospective 2024 study evaluated nearly 700 subjects with type 2 diabetes who were taking a GLP-1 drug and found no association between GLP-1s and worsening retinopathy. Also in 2024, researchers found that patients with type 2 diabetes who were prescribed semaglutide were at greater risk of NAION compared to those who weren't. NAION is a condition that causes sudden blindness, typically just in one eye, due to a lack of blood flow to the optic nerve. The mechanism for why GLP-1 drug use may lead to wet AMD is not well established, but a predominant theory is that lowering blood sugar rapidly leads to a lack of oxygen in the retina. 'When you make the retina more hypoxic, which is what the GLP-1s do, it basically pushes it further over the threshold, causing more abnormal blood vessels to grow,' said Linda Lam, MD, MBA, an ophthalmologist with Keck Medicine of USC, who wasn't involved in the research. Abnormal blood vessel growth in the eye is the hallmark of wet AMD. While GLP-1s offer many health benefits, eye disease risk must be considered in some populations, Lam told Healthline. 'In this particular group of patients who are older, who are diabetics, I really would caution against the extended use of GLP-1s,' she said. Lam reiterated the importance of annual eye exams for the general population, but in particular for those with diabetes, to identify and diagnose eye disease early on. People with type 2 diabetes, especially those taking a GLP-1 drug, should be aware of the signs and symptoms of vision loss and consult with their doctor immediately. These include:

LEADOPTIK Awarded Key Patents Across Three Continents
LEADOPTIK Awarded Key Patents Across Three Continents

Yahoo

time11 hours ago

  • Yahoo

LEADOPTIK Awarded Key Patents Across Three Continents

Strengthening Global IP Portfolio in Optical Imaging for Minimally Invasive Procedures SAN JOSE, Calif., June 6, 2025 /PRNewswire/ -- LEADOPTIK Inc., a Silicon Valley-based medical imaging company, today announced it has been awarded key patents for its proprietary optical probe across three continents: North America, Europe, and Asia. LEADOPTIK designs and manufactures optical probes for minimally invasive procedures, where two critical factors are essential: high-resolution imaging and a miniaturized form factor. High-resolution imaging enables real-time visualization of tissue microstructure, empowering clinicians with the insight needed to make more informed decisions—whether collecting biopsy samples, resecting tumor margins, or delivering therapies to targeted sites. Equally important is miniaturization. Space is at a premium during minimally invasive procedures, and LEADOPTIK's probe is designed with an exceptionally small footprint to navigate tight anatomical pathways without compromising performance. The company's innovation is powered by cutting-edge metasurface technology—flat optical components created through the fusion of nanofabrication and advanced optical design. Unlike traditional optics, metasurfaces enable ultra-thin, high-performance imaging systems that are ideal for integration into medical devices. These three newly granted patents underscore LEADOPTIK's leadership in medical imaging: U.S. Patent (#US11953698B1): Covers a novel device-level metasurface design that significantly extends imaging depth without sacrificing resolution. The patent was granted with 100% of its original claims—a testament to the novelty of LEADOPTIK's approach. European and Japanese Patents (PCT065237 & PCT029301): Protect both the current probe assembly method and alternative configurations that support expanded clinical applications. "Building robust and scalable medical devices is non-negotiable," said Reza Khorasaninejad, CEO and Co-founder of LEADOPTIK. "Our team has not only invented new optical designs but also developed novel methods of integrating them with semiconductor-grade manufacturing processes. These patents reflect our commitment to making next-generation imaging accessible, reliable, and globally protected." "Our intellectual property is the foundation of LEADOPTIK's competitive edge," said Dr. Jiang You, Co-Founder and VP of Medical Imaging. "These patents not only protect our unique optical architecture but also validate the deep technical innovation required to miniaturize high-resolution imaging. It's a major milestone that strengthens our ability to scale globally and expand into new clinical applications." About LEADOPTIK LEADOPTIK is a Silicon Valley-based company pioneering AI-enhanced real-time optical imaging at the point of biopsy. By integrating high-resolution microstructural visualization with emerging analytics, the LIA system bridges the gap between diagnosis, and therapy, supporting more precise and informed decision-making in interventional pulmonology and beyond. For more information, visit Media Contact:hello@ View original content: SOURCE LEADOPTIK Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

‘She always said, 'I'm going to be famous, dad'': Teen dies after viral TikTok ‘dusting' challenge
‘She always said, 'I'm going to be famous, dad'': Teen dies after viral TikTok ‘dusting' challenge

Yahoo

time11 hours ago

  • Yahoo

‘She always said, 'I'm going to be famous, dad'': Teen dies after viral TikTok ‘dusting' challenge

The parents of a 19-year-old who dreamed of fame and died after trying the TikTok 'dusting' trend are warning others about its deadly risks. Renna O'Rourke and her boyfriend DoorDashed aerosol keyboard cleaner to her parents' Tempe, Arizona, home without her mother's knowledge, Dana O'Rourke told 12 News. The dusting trend, also known as chroming or huffing, involves inhaling common household cleaners to get high for views online. The sensation causes brief euphoria but can cause instant, fatal damage, often due to heart failure, according to the Cleveland Clinic. After inhaling the keyboard cleaner, Renna went into cardiac arrest, spent a week unconscious in the intensive care unit, and then was declared brain-dead. Renna's parents described their late daughter as 'vivacious and caring and loyal.' Her father, Aaron O'Rourke, told 12 News that Renna loved to sing and lit up every room with her smile and laughter. 'She always said, 'I'm going to be famous, dad. Just you watch. I'm going to be famous,' and unfortunately, this is not under the most optimal of circumstances,' Aaron O'Rourke, told the outlet.. Despite the less-than-ideal circumstances, the O'Rourke family is now working to honor Renna by spreading the word about the dangers of huffing for teens and parents. 'There's no ID required. It's odorless. It's everything kids look for. They can afford it, they can get it, and it doesn't show in mom and dad's drug test,' Dana O'Rourke told AZ Family about access to the trendy chemicals. She added, 'Don't take your kid's word for it. Dig deep. Search their rooms. Don't trust — and that sounds horrible, but it could save their life.' A GoFundMe started to help the O'Rourke family with hospital bills, burial and therapy costs, and to spread awareness about huffing has surpassed its $5,000 goal and sits at over $9,000 at the time of publication.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store